Mesh Bio DARA and HealthVector Diabetes

Mesh Bio is a Singapore company that applies AI and explainable systems biology to chronic disease. It helps health screening operators, clinics, laboratories and hospitals detect disease risk earlier and cut the manual work of interpreting screening results.

DARA generates automated health screening reports with risk stratification, clinical decision support and referral guidance, and integrates with existing workflows. HealthVector Diabetes models disease progression to predict complications in patients with diabetes, supporting personalised risk assessment and treatment optimisation. The platform structures data from multiple sources, runs it through a clinical intelligence engine and returns personalised reports. Users include private healthcare groups, diagnostic laboratories and public hospitals in Asia.

• DARA automated screening: AI-generated health screening reports with risk stratification.
• Result interpretation: clinical decision support that explains abnormal results for clinicians and patients.
• Referral guidance: suggests the next clinical step so screening findings lead to follow-up.
• HealthVector Diabetes: disease progression modelling to predict diabetes complications.
• Chronic disease coverage: models for diabetes, kidney disease, cardiovascular disease, hypertension and stroke.
• Workflow integration: structures data from multiple sources and fits existing clinic workflows.

Health check-up centers in Vietnam could automate corporate screening reports with risk stratification and referral advice. Diagnostic laboratory chains could offer AI-interpreted reports to win and retain corporate clients. Endocrinology clinics could predict kidney and cardiovascular complications in diabetes patients.

Reduces manual report generation by 90%, according to the company. Parkway Shenton saved 200K USD and increased revenue by 23% after automating health screening reports. Fullerton Health improved early risk detection by 30%. Predictive models can flag at-risk patients up to 10 years before clinical diagnosis.

Chronic diseases such as diabetes, kidney disease and hypertension are rising across Asia, and private screening providers compete on the quality of reports and follow-up. Corporate health check-ups are a large market in Vietnam, where clinics are looking for ways to turn results into actionable risk insights.

Mesh Bio Pte. Ltd. is based in Singapore and reports 300K+ patients assessed and 40+ healthcare groups onboarded across Asia. Recognition includes the OCBC Emerging Enterprise Award and Forbes Asia '100 to Watch'. Organisations listed include Enterprise Singapore, Singapore General Hospital and Tan Tock Seng Hospital.